Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Interim evaluation of the treatment of Recalcitrant Atopic Blepharo-Keratoconjunctivitis (ABKC)
Author Affiliations & Notes
  • Paul J Gomes
    Allergy, Ora, Inc., Andover, Massachusetts, United States
  • Sadie Burnham
    Ora, Inc., Andover, Massachusetts, United States
  • Mark B Abelson
    Andover Eye Associates, Andover, Massachusetts, United States
    Ora, Inc., Andover, Massachusetts, United States
  • Kara Quealy
    Ora, Inc., Andover, Massachusetts, United States
  • Leslie O'Dell
    Ora, Inc., Andover, Massachusetts, United States
  • Laura M M Periman
    Periman Eye Institute, Washington, United States
  • Sathi Maiti
    Periman Eye Institute, Washington, United States
  • Footnotes
    Commercial Relationships   Paul Gomes Ora, Inc, Code E (Employment); Sadie Burnham Ora, Inc, Code E (Employment); Mark Abelson Ora, Inc, Code E (Employment), Regeneron Grant, Code F (Financial Support); Kara Quealy Ora, Inc, Code E (Employment); Leslie O'Dell Ora, Inc, Code E (Employment); Laura M Periman Regeneron Grant, Code F (Financial Support); Sathi Maiti Periman Eye Institute, Code E (Employment)
  • Footnotes
    Support  Regeneron Investigator-Initiated Research Grant R668-OD-1829
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1956. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul J Gomes, Sadie Burnham, Mark B Abelson, Kara Quealy, Leslie O'Dell, Laura M M Periman, Sathi Maiti; Interim evaluation of the treatment of Recalcitrant Atopic Blepharo-Keratoconjunctivitis (ABKC). Invest. Ophthalmol. Vis. Sci. 2024;65(7):1956.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : DUPIXENT (dupilumab) is a subcutaneous (SQ) injection for the treatment of uncontrolled moderate-to-severe eczema as well as atopic dermatitis. Atopic Blepharo-Keratoconjunctivitis (ABKC) is a serious allergic eye condition with the potential to impair vision due to prolonged inflammation of the ocular surface. Diagnosing and treating ABKC is clinically challenging owing to the limited therapeutic options. Additionally, ABKC imposes a significant burden on the patient's quality of life. This study investigates the efficacy of dupilumab in the treatment of signs and symptoms of ABKC.

Methods : A multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study enrolled 20 subjects with ABKC. Subjects were randomized in a 2:1 ratio of dupilumab:placebo. This study consists of seven office visits over a period of approximately 126 days (18 weeks-Phase I), with the option to continue to an additional four visits, open label over a period of approximately 112 days (16 weeks- Extension Phase). Following initial loading dose, future dosing was 300 mg SQ injection. Trained personnel administered the initial injection while the second injection of dupilumab or placebo and all future injections were either self-administered by the patient or administered by a caregiver under the observation of qualified staff. During those 7 office visits for phase I and 4 additional visits for extension phase, subjects were evaluated and had external photos taken and answered symptom related questions. In between visits subjects filled out a paper diary daily at home.

Results : This is an interim analysis. There have been over 2,500 hundred treatment days, approximately 2/3 drug and 1/3 placebo. No treatment emergent adverse events to date. Significant symptomatic improvement has been seen in participants by the sixth visit, as illustrated in figure 1.

Conclusions : This interim analysis of dupilumab for the treatment of ABKC as a new indication of treatment. There are no significant safety concerns to date. Some subjects have shown clinically meaningful improvement. Unmasking and the open-label phase of the study are expected in 2024.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×